Form 4: 89bio Director Disposes Options in Roche Merger

89bio Director Edward Atkinson III disposed of stock options as part of the company's acquisition by Roche Holdings, Inc. for $14.50 cash plus CVRs.

Summary

• Director Edward Morrow Atkinson III disposed of all his stock options in 89bio, Inc. on October 30, 2025.
• The disposition occurred as a result of the merger between 89bio, Inc. and Roche Holdings, Inc., through its subsidiary Bluefin Merger Subsidiary, Inc.
• The merger involved a tender offer where shareholders received $14.50 per share in cash (the "Closing Amount") plus one non-tradeable Contingent Value Right (CVR) per share.
• Each CVR represents the right to receive certain contingent payments of up to an aggregate amount of $6.00 per share upon the achievement of specified milestones.
• Immediately prior to the merger, outstanding stock options became fully vested and exercisable.
• Unexercised options were cancelled and converted into the right to receive cash equal to the product of (Closing Amount exercise price) and the number of shares, plus one CVR per share.
• Options with an exercise price equal to or greater than the Closing Amount ($14.50) but less than $20.50 (Out of the Money Options) were converted into the right to receive CVRs and potential future cash payments tied to milestone achievements.
• Options with an exercise price equal to or greater than $20.50 were cancelled without any payment.

Sentiment

Score: 7

Explanation: The sentiment is generally positive for shareholders and option holders due to the successful completion of the merger, providing immediate cash and potential future upside through CVRs. However, the company ceases to exist as an independent entity, and some options were cancelled without payment.

Positives

• The merger provides immediate liquidity for 89bio, Inc. shareholders and option holders through a cash payment of $14.50 per share.
• Contingent Value Rights (CVRs) offer potential additional upside of up to $6.00 per share if specified milestones are achieved.
• Director Atkinson received cash and CVRs for his in-the-money stock options, realizing value from his holdings.

Negatives

• 89bio, Inc. ceases to be an independent publicly traded company following the acquisition by Roche Holdings, Inc.
• Stock options with an exercise price equal to or greater than $20.50 were cancelled without any payment.
• The CVRs are non-tradeable, limiting immediate liquidity and market valuation for the contingent portion of the consideration.

Risks

• The achievement of specified milestones for CVR payments is uncertain and depends on future events, meaning the full $6.00 per share may not be realized.
• The non-tradeable nature of the CVRs means holders cannot sell them for immediate cash, and their value is only realized upon milestone achievement or expiration.

Future Outlook

The future value for former 89bio shareholders and option holders who received CVRs depends entirely on the achievement of specified milestones, which could result in additional payments of up to $6.00 per share. 89bio, Inc. will operate as a wholly-owned subsidiary of Roche Holdings, Inc.

Industry Context

This acquisition by Roche Holdings, Inc. reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger companies acquire smaller, innovative firms to expand their pipelines and market reach. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks and rewards, particularly for assets in clinical development.

Comparison to Industry Standards

• The use of CVRs in this acquisition aligns with industry trends in biotech M&A, where such instruments are frequently employed to manage risk and reward for assets with uncertain future clinical or commercial success.
• Similar CVR structures have been observed in other significant biotech acquisitions, such as Celgene's acquisition of Receptos or Sanofi's acquisition of Principia Biopharma, where payments were tied to regulatory approvals or sales milestones.
• The total potential consideration of $20.50 per share (cash plus maximum CVR) would be assessed against 89bio's pre-announcement market valuation and comparable transactions in the NASH or metabolic disease therapeutic areas to determine its competitiveness.

Stakeholder Impact

• Shareholders: Received cash and CVRs, providing liquidity and potential future upside.
• Option Holders: Received cash and CVRs for in-the-money options, while some out-of-the-money options received CVRs or were cancelled.
• Employees: 89bio, Inc. continues as a subsidiary, implying continued operations, though potential organizational changes under new ownership are possible.
• Roche Holdings, Inc.: Expanded its pharmaceutical pipeline and market presence through the acquisition of 89bio's assets.

Next Steps

• Monitoring the achievement of specified milestones that trigger payments under the Contingent Value Rights Agreement.
• Integration of 89bio, Inc. into Roche Holdings, Inc. as a wholly-owned subsidiary.

Key Dates

Keywords

89bio, ETNB, Roche Holdings, Merger, Acquisition, Stock Options, Form 4, Insider Transaction, Contingent Value Right, CVR, Biotechnology, Pharmaceutical